Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: purified talc; hypromellose phthalate; triethyl citrate; titanium dioxide; hyprolose; hypromellose; crospovidone; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: hyprolose; purified talc; triethyl citrate; crospovidone; titanium dioxide; hypromellose phthalate; hypromellose; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: purified talc; crospovidone; titanium dioxide; hypromellose; triethyl citrate; hyprolose; hypromellose phthalate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: crospovidone; titanium dioxide; hyprolose; hypromellose phthalate; triethyl citrate; hypromellose; purified talc; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: titanium dioxide; purified talc; hyprolose; hypromellose; hypromellose phthalate; crospovidone; triethyl citrate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Spojené štáty - angličtina - NLM (National Library of Medicine)

rebel distributors corp - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with narrow-angle glaucoma or urinary retentio

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 33.68 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; lactose monohydrate; croscarmellose sodium; dichloromethane; polysorbate 80; hypromellose; pregelatinised maize starch; magnesium stearate; methanol; purified talc; isopropyl alcohol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; ethanol; strong ammonia solution; iron oxide black; indigo carmine; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - methyldopa (anhydrous) - oral tablet - 500mg

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amantadine hydrochloride, quantity: 100 mg - capsule, soft - excipient ingredients: titanium dioxide; glycerol; lecithin; sodium propyl hydroxybenzoate; yellow beeswax; partially hydrogenated soya oil; iron oxide red; gelatin; sodium ethyl hydroxybenzoate; hydrogenated soya oil; rape seed oil; maize starch; sorbitol; mannitol; ethyl acetate; butan-1-ol; shellac; industrial methylated spirit - parkinson's disease: idiopathic parkinson's disease; post encephalitic parkinsonism; symptomatic parkinsonism (e.g. following cns injury from carbon monoxide poisoning); arteriosclerotic parkinsonism; drug-induced extrapyramidal reactions. symmetrel can be given alone for initial therapy or combined with anticholinergic drugs or l-dopa (see "dosage and administration"). note: symmetrel is not indicated for the treatment of tardive dyskinesia. type a virus influenza: prophylaxis of respiratory tract illness caused by influenza type a. prophylaxis in non-immunized individuals (including children) for whom influenza may have serious consequences (e.g. persons with chronic respiratory disease of diabetes mellitus).

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - trazodone hydrochloride - capsule, hard - 50 milligram(s) - other antidepressants; trazodone